TheStreet.com  Jan 27  Comment 
TheStreet is providing FREE access to Jim Cramer’s charitable trust (Action Alerts PLUS) and his premium articles on Real Money this weekend. Please register here. Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad...
Benzinga  Jan 16  Comment 
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) pipeline and existing products could drive a doubling of revenue every four years, an analyst said Friday. Nomura's M. Ian Somaiya boosted his target on the company by 6 percent to $123, maintaining...
TheStreet.com  Jan 16  Comment 
 Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener. NEW YORK (TheStreet) -- Here are some of the hot stocks Jim Cramer talked about on Thursday's Mad Money on CNBC: NVAX data by YCharts...
Benzinga  Jan 14  Comment 
In a report published Wednesday, Nomura analyst Ian Somaiya reiterated a Buy rating on BioMarin Pharmaceutical (NASDAQ: BMRN), and raised the price target from $114.00 to $116.00. In the report, Nomura noted, “We are increasing our TP on BMRN...
TheStreet.com  Jan 12  Comment 
SAN FRANCISCO (TheStreet) -- It's rare to hear a biotech CEO mention a competing company by name when speaking in public. Like politicians, CEOs would rather acknowledge their rivals with generalities. BioMarin Pharmaceuticals CEO Jean-Jacques...
Motley Fool  Jan 9  Comment 
Sarepta Therapeutics slumped by a double-digit percentage in December. Find out what's behind the move and whether or not shares are a bargain after their tumble.
Market Intelligence Center  Jan 5  Comment 
Friday’s trading in BioMarin Pharmaceutical (BMRN) gives options traders an opportunity for a 3.52% return. By selling the Apr. '15 $90.00 call and buying the Jan. '16 call at the $65.00 level for a net debit of $24.15, traders will book a...
Forbes  Dec 24  Comment 
Investors in BioMarin Pharmaceutical Inc. (NASD: BMRN) saw new options begin trading this week, for the February 2015 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BMRN options chain for the new February...
Market Intelligence Center  Dec 24  Comment 
After closing Tuesday at $87.29, BioMarin Pharmaceutical (BMRN) presents an attractive opportunity to get a 5.47% return in just 58 days, which is an annualized return of 34.44% (for comparison purposes only). To enter this trade, sell one Feb....


BioMarin Pharmaceutical Inc. (BMRN), a developer of enzyme-related therapies (ERT), co-markets Aldurazyme with Genzyme Corporation (GENZ) for the treatment of MPS-I (mucopolysaccharidosis). MPS-I is a rare genetic enzyme deficiency disorder, afflicting roughly 3,000 people worldwide, caused by the lack of a specific enzyme involved in lysosomal storage. More common names for mucopolysaccharidosis are Hurler's Syndrome, Hurler-Scheie, and Scheie's Disease. The company's other developed product, Naglazyme, for MPS-VI, recently entered the market. MPS-VI is also a rare genetic enzyme deficiency disorder, with an estimated 1,100 people suffering from it worldwide. The company's third lead drug, Kuvan, received FDA approval for the treatment of PKU in December 2007. With the recent launch of Kuvan, the company now has three products on the market. The company also receives royalties and license revenue on sales of the Orapred franchise from Alliant Pharmaceuticals. In 2004, the company acquired Orapred, a grape-flavored oral corticosteroid liquid for the treatment of severe asthma in children and subsequently licensed the franchise to Alliant Pharmaceuticals in March 2006. BioMarin, headquartered in Novato, CA, employs roughly 300 people.

Business Overview

Business & Financial Metrics

In 2009, BMRN incurred a net loss of $488 thousand on revenues of $324.7 million. This represents a real turnaround from 2008, when the company earned $30.8 million on $296.5 million in revenues.[1]

Geographical Distribution[2]

BioMarin generates the majority of its revenues from sales in Europe.



BioMarin competes with companies like:


  1. BMRN 2009 10-K pg. 36  
  2. 2.0 2.1 BMRN 2009 10-K pg. 16  
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki